atorvastatin has been researched along with Adverse Drug Event in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (32.14) | 29.6817 |
| 2010's | 12 (42.86) | 24.3611 |
| 2020's | 7 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Ding, D; Fang, H; Kelly, R; Liu, Z; Shi, Q; Tong, W | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| El Hamdaoui, H; Elens, L; Haufroid, V; Horion, S; Hoste, E; Muccioli, GG; Panin, N; Paquot, A | 1 |
| Chen, NN; Li, JX; Ma, XD; Su, SW; Wang, CC; Wang, KX; Wu, YZ; Xiong, C | 1 |
| Li, XY; Mao, YM; Zhong, W | 1 |
| Adams, SP; Alaeiilkhchi, N; Tasnim, S; Wright, JM | 1 |
| Patrono, C; Pedicino, D | 1 |
| Hale, G; Lyver, E; Stein, B; Ward, T | 1 |
| Armitage, J; Beaumont, D; Brack, K; Goldacre, B; Herrett, E; MacDonald, T; Prowse, D; Roberts, I; Shakur-Still, H; Smeeth, L; Staa, TV; Williamson, E; Youssouf, N | 1 |
| Garcia, B; Halvorsen, KH; Samdal, H; Svendsen, K; Vorren, S | 1 |
| Bohn, JM; Connolly, JG; Desai, RJ; Fischer, MA; Gagne, JJ; Kesselheim, AS; Khan, NF; Rogers, JR; Sarpatwari, A | 1 |
| Baggett, MC; Nykamp, D | 1 |
| Hunter, ML; Mahvan, TD; Mlodinow, SG; Onysko, MK; Vandiver, JW | 1 |
| Božina, N; Ganoci, L; Macolić Šarinić, V; Mirošević Skvrce, N; Muačević Katanec, D; Šimić, I | 1 |
| Dhopeshwarkar, N; Goss, F; Lai, K; Rozenblum, R; Sa'adon, R; Seger, DL; Topaz, M; Zhou, L | 1 |
| Bao, W; Chan, JC; Fayyad, R; Kong, AP; Laskey, R | 1 |
| Audenrode, MV; Cremieux, P; Duh, MS; Greenberg, P; Karner, P; Vekeman, F; Zhang, H | 1 |
| Agnew-Blais, J; Choudhry, NK; Parker, RM; Shekelle, P; Shrank, WH; Wolf, MS | 1 |
| Jewells, V; Markovic-Plese, S; Speer, D | 1 |
| Kukes, IV; Paukov, SV; Ruvinov, IuV; Sivkov, AS | 1 |
| Becker, ML; Elens, LL; Hofman, A; Stricker, BH; Uitterlinden, AG; van Schaik, RH; Visser, LE | 1 |
| Cassels, A; Cole, C; Hughes, MA; Lexchin, J; McCormack, JP; Mintzes, B | 1 |
| Cárcamo, CA; Celedón, C; Nygren, CE; Paulós, CP | 1 |
| Guthrie, RM | 1 |
| McHugh, A | 1 |
| Andrade, RJ; Barriocanal, A; Borraz, Y; Costa, J; Durán, JA; Fernández, MC; García-Cortés, M; García-Muņoz, B; Guarner, C; Hidalgo, R; Kaplowitz, N; Lucena, MI; Muņoz-Yagüe, T; Pachkoria, K; Pelaez, G; Planas, R; Rodrigo, L; Romero-Gomez, M; Salmerón, J | 1 |
| Hanson, ML; Kelly, SE; Richards, SM | 1 |
2 review(s) available for atorvastatin and Adverse Drug Event
| Article | Year |
|---|---|
Pravastatin for lowering lipids.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Drug-Related Side Effects and Adverse Reactions; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infant; Infant, Newborn; Pravastatin; Rosuvastatin Calcium | 2023 |
How safe is aggressive statin therapy?
Topics: Atorvastatin; Chemical and Drug Induced Liver Injury; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Muscular Diseases; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
2 trial(s) available for atorvastatin and Adverse Drug Event
| Article | Year |
|---|---|
Study protocol for statin web-based investigation of side effects (StatinWISE): a series of randomised controlled N-of-1 trials comparing atorvastatin and placebo in UK primary care.
Topics: Atorvastatin; Cardiovascular Diseases; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Evidence-Based Medicine; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Primary Health Care; Randomized Controlled Trials as Topic; Treatment Outcome; United Kingdom | 2017 |
Impact of a pharmaceutical care program in a community pharmacy on patients with dyslipidemia.
Topics: Aged; Atorvastatin; Chile; Community Pharmacy Services; Drug-Related Side Effects and Adverse Reactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Patient Compliance; Patient Education as Topic; Patient Satisfaction; Pyrroles; Quality of Life | 2005 |
24 other study(ies) available for atorvastatin and Adverse Drug Event
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Models, Biological; Predictive Value of Tests | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Genetic Polymorphisms in SLCO2B1 and ABCC1 Conjointly Modulate Atorvastatin Intracellular Accumulation in HEK293 Recombinant Cell Lines.
Topics: Atorvastatin; Chromatography, Liquid; Drug-Related Side Effects and Adverse Reactions; HEK293 Cells; Humans; Multidrug Resistance-Associated Proteins; Organic Anion Transporters; Polymorphism, Single Nucleotide; Tandem Mass Spectrometry | 2023 |
Therapeutic effects of atorvastatin on doxorubicin-induced hepatotoxicity in rats via antioxidative damage, anti-inflammatory, and anti-lipotoxicity.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Apoptosis; Atorvastatin; Chemical and Drug Induced Liver Injury; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Oxidative Stress; Rats | 2023 |
[Statin-related drug-induced liver injury].
Topics: Atorvastatin; Chemical and Drug Induced Liver Injury; Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Simvastatin | 2023 |
Adverse effects of anthracyclines: does atorvastatin STOP-CArdiotoxicity?
Topics: Anthracyclines; Antibiotics, Antineoplastic; Atorvastatin; Cardiotoxicity; Drug-Related Side Effects and Adverse Reactions; Humans; Neoplasms | 2023 |
Safety of High-Intensity Statins in the Veteran Population: Atorvastatin 40 to 80 mg Compared With Rosuvastatin 20 to 40 mg.
Topics: Aged; Atherosclerosis; Atorvastatin; Cohort Studies; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Odds Ratio; Retrospective Studies; Rosuvastatin Calcium; Veterans | 2020 |
Adverse drug reaction reporting: how can drug consumption information add to analyses using spontaneous reports?
Topics: Adverse Drug Reaction Reporting Systems; Atorvastatin; Central Nervous System Stimulants; Databases, Factual; Drug Utilization Review; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Methylphenidate; Norway; Pharmaceutical Services; Pharmacovigilance; Risk Factors; Sex Factors; Simvastatin | 2018 |
Effect of Lawyer-Submitted Reports on Signals of Disproportional Reporting in the Food and Drug Administration's Adverse Event Reporting System.
Topics: Adverse Drug Reaction Reporting Systems; Atorvastatin; Dermatologic Agents; Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isotretinoin; Lawyers; Rosuvastatin Calcium; United States; United States Food and Drug Administration | 2019 |
Statin-Associated Bilateral Foot Myopathy.
Topics: Adult; Atorvastatin; Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Muscular Diseases; Rhabdomyolysis | 2020 |
Statin adverse effects: sorting out the evidence.
Topics: Atorvastatin; Clinical Trials as Topic; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Evidence-Based Practice; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Outcome Assessment, Health Care; Practice Guidelines as Topic; Pyrroles; Rhabdomyolysis; Risk Adjustment; Ubiquinone; Vitamins | 2014 |
ABCG2 gene polymorphisms as risk factors for atorvastatin adverse reactions: a case-control study.
Topics: Adult; Asian People; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cytochrome P-450 CYP3A; Drug-Related Side Effects and Adverse Reactions; Female; Genetic Association Studies; Genotype; Humans; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Neoplasm Proteins; Organic Anion Transporters; Polymorphism, Single Nucleotide; Risk Factors | 2015 |
Clinicians' Reports in Electronic Health Records Versus Patients' Concerns in Social Media: A Pilot Study of Adverse Drug Reactions of Aspirin and Atorvastatin.
Topics: Adverse Drug Reaction Reporting Systems; Aspirin; Atorvastatin; Drug-Related Side Effects and Adverse Reactions; Electronic Health Records; Exanthema; Humans; Musculoskeletal Pain; Physician's Role; Pilot Projects; Social Media | 2016 |
Safety of atorvastatin in Asian patients within clinical trials.
Topics: Aged; Asia; Asian People; Atorvastatin; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Patient Safety; Patient Selection; Randomized Controlled Trials as Topic; Research Subjects; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2016 |
Can social media data lead to earlier detection of drug-related adverse events?
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Atorvastatin; Cyclobutanes; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Pharmacovigilance; Social Media; Time Factors; United States; United States Food and Drug Administration | 2016 |
Variability in pharmacy interpretations of physician prescriptions.
Topics: Alendronate; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Bone Density Conservation Agents; Comprehension; Contraindications; Drug Information Services; Drug Labeling; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Education, Pharmacy; Educational Status; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ibuprofen; Patient Education as Topic; Pharmaceutical Preparations; Pharmacies; Professional Competence; Pyrroles; Trimethoprim, Sulfamethoxazole Drug Combination; Urban Health Services; Writing | 2009 |
Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis.
Topics: Anticholesteremic Agents; Atorvastatin; Central Nervous System; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Heptanoic Acids; Humans; Iatrogenic Disease; Immunologic Factors; Interferon-beta; Multiple Sclerosis; Pyrroles; Risk Assessment | 2009 |
[Individual pharmacotherapy safety in the assessment of cytochrome P-450 3A4 (CYP3A4) isoenzyme activity].
Topics: Atorvastatin; Clinical Trials as Topic; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Enzyme Induction; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Ischemia; Pharmacokinetics; Platelet Aggregation Inhibitors; Precision Medicine; Pyrroles; Ticlopidine | 2010 |
Genetic variation in the ABCC2 gene is associated with dose decreases or switches to other cholesterol-lowering drugs during simvastatin and atorvastatin therapy.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Genetic Association Studies; Haplotypes; Heptanoic Acids; Humans; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Polymorphism, Single Nucleotide; Proportional Hazards Models; Pyrroles; Simvastatin | 2013 |
Drugs in the news: an analysis of Canadian newspaper coverage of new prescription drugs.
Topics: Acetamides; Advertising; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antiviral Agents; Atorvastatin; Bibliometrics; Canada; Celecoxib; Cholinesterase Inhibitors; Consumer Product Safety; Disclosure; Donepezil; Drug Industry; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Estrogen Antagonists; Heptanoic Acids; Humans; Indans; Newspapers as Topic; Oseltamivir; Patient Education as Topic; Piperidines; Pyrazoles; Pyrroles; Raloxifene Hydrochloride; Sulfonamides | 2003 |
Fake drugs: a problem for all.
Topics: Atorvastatin; Drug Industry; Drug-Related Side Effects and Adverse Reactions; Fraud; Heptanoic Acids; Humans; Pyrroles | 2006 |
Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Atorvastatin; Azepines; Captopril; Cardiovascular Agents; Central Nervous System Agents; Chemical and Drug Induced Liver Injury; Chronic Disease; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Heptanoic Acids; Humans; Liver; Liver Diseases; Male; Middle Aged; Pyrroles; Registries; Spain | 2006 |
Zooplankton chitobiase activity as an endpoint of pharmaceutical effect.
Topics: Acetylglucosaminidase; Animals; Atorvastatin; Biological Assay; Daphnia; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Environmental Monitoring; Fluoxetine; Heptanoic Acids; Lethal Dose 50; Lovastatin; Pyrroles; Sertraline; Water Pollutants, Chemical; Xenobiotics; Zooplankton | 2008 |